Table 1.
Participant characteristics, conditions and outcomes in each therapy categorya
| Participant characteristics and outcomes | Therapy | |||
|---|---|---|---|---|
|
| ||||
| Antiplatelets (N = 901) | VKA (N = 1450) | Antiplatelets plus VKA (N = 576) | NOACs (N = 439) | |
| Age, years | ||||
| Mean (SD) | 79.6 (10.3) | 75.3 (10.3) | 74.6 (9.4) | 75.5 (9.6) |
|
| ||||
| Sex | ||||
| Female, n (%) | 460 (51.1) | 739 (50.0) | 223 (38.7) | 226 (51.5) |
|
| ||||
| CHA2DS2-VASc score | 4 | 4 | 4 | 4 |
| Median (IQR) | (3–5) | (3–5) | (3–5) | (3–5) |
|
| ||||
| English Index of Deprivation Score (N= 3646) | 43.4 | 42.1 | 42.7 | 41.8 |
| Median (IQR) | (37.6–49.8) | (36.2–48.8) | (36.6–49.4) | (35.3–48.3) |
|
| ||||
| Exposure, days | ||||
| Mean (SD) | 897 (633) | 1288 (616) | 764 (623) | 438 (407) |
|
| ||||
| TIA or IS | ||||
| n (%) | 117 (13.0) | 132 (9.1) | 30 (5.2) | 14 (3.2) |
|
| ||||
| CHD | ||||
| n (%) | 189 (21.0) | 256 (17.7) | 162 (28.1) | 27 (6.2) |
|
| ||||
| PAD | ||||
| n (%) | 32 (3.6) | 39 (2.7) | 20 (3.5) | 6 (1.4) |
|
| ||||
| GI haemorrhage | ||||
| n (%) | 36 (4.0) | 43 (3.0) | 17 (3.0) | 7 (1.6) |
a
Data show the participants who took each drug. Those who took no drugs at all, or took combinations that were not of interest in the study, that is, VKA+NOACs, are not presented. CHD = cardiovascular disease. GI = gastrointestinal. IQR = interquartile range. IS = ischaemic stroke. NOACs = novel oral anticoagulants. PAD = peripheral artery disease. SD = standard deviation. TIA = transient ischaemic attack. VKA = vitamin K antagonists.